Williams Paul Anthony, the Senior Vice President of Products Business at Emergent BioSolutions Inc., recently sold 3,000 shares of the company's stock. This transaction took place on October 1, 2026, and is part of a trading plan established on November 14, 2025. This plan is designed to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934.
Emergent BioSolutions, headquartered in Gaithersburg, Maryland, is a key player in the pharmaceutical preparations industry. The company focuses on developing and manufacturing vaccines and therapeutics for public health needs. With a fiscal year ending on December 31, Emergent BioSolutions continues to adapt to the evolving landscape of the life sciences sector.
According to the recent SEC filing, the shares were sold at a weighted average price of $6.53, with individual transaction prices ranging from $6.52 to $6.56. Following this transaction, Williams Paul Anthony now owns 156,098 shares of Emergent BioSolutions.
This sale may have implications for the company's perception in the market, as insider trading activity can influence investor confidence. The pharmaceutical industry, characterized by its regulatory complexities and competitive landscape, is closely monitored by investors and analysts alike.
Details were not available in the SEC filing regarding any future plans or additional transactions from Williams Paul Anthony.